EP2035005A4 - Therapy using cytokine inhibitors - Google Patents

Therapy using cytokine inhibitors

Info

Publication number
EP2035005A4
EP2035005A4 EP07798190A EP07798190A EP2035005A4 EP 2035005 A4 EP2035005 A4 EP 2035005A4 EP 07798190 A EP07798190 A EP 07798190A EP 07798190 A EP07798190 A EP 07798190A EP 2035005 A4 EP2035005 A4 EP 2035005A4
Authority
EP
European Patent Office
Prior art keywords
therapy
cytokine inhibitors
cytokine
inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP07798190A
Other languages
German (de)
French (fr)
Other versions
EP2035005A2 (en
Inventor
Constance A Crowley
Nancy G J Delaet
Justin Ernst
Carrie Gail Grove
Bonnie Hepburn
Bernard King
Christopher J Larson
Stephen Miller
Kent Pryor
Lewis J Shuster
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kemia Inc
Original Assignee
Kemia Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kemia Inc filed Critical Kemia Inc
Publication of EP2035005A2 publication Critical patent/EP2035005A2/en
Publication of EP2035005A4 publication Critical patent/EP2035005A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EP07798190A 2006-06-09 2007-06-06 Therapy using cytokine inhibitors Withdrawn EP2035005A4 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US81226806P 2006-06-09 2006-06-09
US83307806P 2006-07-24 2006-07-24
US83527006P 2006-08-03 2006-08-03
PCT/US2007/070547 WO2007146712A2 (en) 2006-06-09 2007-06-06 Therapy using cytokine inhibitors

Publications (2)

Publication Number Publication Date
EP2035005A2 EP2035005A2 (en) 2009-03-18
EP2035005A4 true EP2035005A4 (en) 2011-07-06

Family

ID=38832677

Family Applications (1)

Application Number Title Priority Date Filing Date
EP07798190A Withdrawn EP2035005A4 (en) 2006-06-09 2007-06-06 Therapy using cytokine inhibitors

Country Status (8)

Country Link
EP (1) EP2035005A4 (en)
AR (1) AR061273A1 (en)
AU (1) AU2007257959A1 (en)
CA (1) CA2691214A1 (en)
CL (1) CL2007001670A1 (en)
PE (1) PE20080935A1 (en)
TW (1) TW200814998A (en)
WO (1) WO2007146712A2 (en)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2008010187A (en) 2006-02-10 2008-10-31 Summit Corp Plc Treatment of duchenne muscular dystrophy.
US7989459B2 (en) 2006-02-17 2011-08-02 Pharmacopeia, Llc Purinones and 1H-imidazopyridinones as PKC-theta inhibitors
US7902187B2 (en) 2006-10-04 2011-03-08 Wyeth Llc 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression
TW200837064A (en) 2006-10-04 2008-09-16 Pharmacopeia Inc 8-substituted 2-(benzimidazolyl)purine derivatives for immunosuppression
TW200831104A (en) 2006-10-04 2008-08-01 Pharmacopeia Inc 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression
US8563573B2 (en) 2007-11-02 2013-10-22 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
US7902248B2 (en) 2006-12-14 2011-03-08 Hoffmann-La Roche Inc. Oxime glucokinase activators
CN101801187B (en) * 2007-07-13 2014-07-23 得克萨斯系统大学评议会 Heterocyclic modulators of cannabinoid receptors
JP2010535708A (en) 2007-08-03 2010-11-25 ビオマリン アイジーエー リミテッド Drug combinations for the treatment of Duchenne muscular dystrophy
CA2726588C (en) 2008-06-03 2019-04-16 Karl Kossen Compounds and methods for treating inflammatory and fibrotic disorders
CN102272120B (en) * 2008-11-07 2013-12-25 H.隆德贝克有限公司 Biologically active amides
EP2438059A1 (en) 2009-06-05 2012-04-11 Link Medicine Corporation Aminopyrrolidinone derivatives and uses thereof
US20110117055A1 (en) * 2009-11-19 2011-05-19 Macdonald James E Methods of Treating Hepatitis C Virus with Oxoacetamide Compounds
US8663661B2 (en) * 2009-12-23 2014-03-04 Ratiopharm Gmbh Solid pharmaceutical dosage form of ticagrelor
US8802868B2 (en) 2010-03-25 2014-08-12 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
JP6155187B2 (en) 2010-03-30 2017-06-28 ヴァーセオン コーポレイション Polysubstituted aromatic compounds as inhibitors of thrombin
MX353408B (en) 2010-04-22 2018-01-11 Vertex Pharma Process of producing cycloalkylcarboxamido-indole compounds.
US9133123B2 (en) 2010-04-23 2015-09-15 Cytokinetics, Inc. Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use
AR081331A1 (en) 2010-04-23 2012-08-08 Cytokinetics Inc AMINO- PYRIMIDINES COMPOSITIONS OF THE SAME AND METHODS FOR THE USE OF THE SAME
AR081626A1 (en) 2010-04-23 2012-10-10 Cytokinetics Inc AMINO-PYRIDAZINIC COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND USE OF THE SAME TO TREAT CARDIAC AND SKELETIC MUSCULAR DISORDERS
US8759380B2 (en) 2011-04-22 2014-06-24 Cytokinetics, Inc. Certain heterocycles, compositions thereof, and methods for their use
SE1450131A1 (en) 2011-10-21 2014-05-07 Abbvie Inc DAA combination therapy (eg with ABT-072 or ABT-333) for use in the treatment of HCV
DE112012002748T5 (en) 2011-10-21 2014-07-31 Abbvie Inc. Method for the treatment of HCV comprising at least two direct-acting antiviral agents, ribavirin but not interferon
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
AR092742A1 (en) 2012-10-02 2015-04-29 Intermune Inc ANTIFIBROTIC PYRIDINONES
CN110179795A (en) 2013-03-15 2019-08-30 维颂公司 The pharmaceutical applications of polysubstituted aromatic compounds as serpin
MX382781B (en) 2014-04-02 2025-03-13 Intermune Inc ANTI-FIBROTIC PYRIDINONES.
RU2744460C2 (en) 2014-04-15 2021-03-09 Вертекс Фармасьютикалз Инкорпорейтед Pharmaceutical compositions for treating diseases mediated by cystic fibrosis transmembrane conductance regulator
US10189810B2 (en) 2014-09-17 2019-01-29 Verseon Corporation Pyrazolyl-substituted pyridone compounds as serine protease inhibitors
JP2017537940A (en) 2014-12-10 2017-12-21 マサチューセッツ インスティテュート オブ テクノロジー Fused 1,3-azole derivatives useful for the treatment of proliferative diseases
CN107405333A (en) 2015-02-27 2017-11-28 维颂公司 Substituted pyrazole compound as serpin
CA3021424C (en) 2015-06-12 2023-03-21 University Of Greenwich Triazine derivatives as interferon-gamma inhibitors
EP3365340B1 (en) 2015-10-19 2022-08-10 Incyte Corporation Heterocyclic compounds as immunomodulators
US20170145025A1 (en) 2015-11-19 2017-05-25 Incyte Corporation Heterocyclic compounds as immunomodulators
CN109071516B (en) 2015-12-15 2021-08-31 阿斯利康(瑞典)有限公司 novel compound
ES2916874T3 (en) 2015-12-17 2022-07-06 Incyte Corp N-phenyl-pyridine-2-carboxamide derivatives and their use as modulators of the PD-1/PD-L1 protein/protein interaction
AU2016379372A1 (en) 2015-12-22 2018-08-02 Incyte Corporation Heterocyclic compounds as immunomodulators
CN109071456A (en) 2016-02-16 2018-12-21 麻省理工学院 MAX binding agents as MYC modulators and uses thereof
EA201892448A1 (en) 2016-04-28 2019-06-28 Эмори Юниверсити ALKYN-CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND RELATED APPLICATION METHODS
ES2906460T3 (en) 2016-05-06 2022-04-18 Incyte Corp Heterocyclic compounds as immunomodulators
ES2905980T3 (en) 2016-05-26 2022-04-12 Incyte Corp Heterocyclic compounds as immunomodulators
ES2866883T3 (en) * 2016-06-08 2021-10-20 Support Venture Gmbh Pharmaceutical combinations for the treatment of cancer
BR112018076534A2 (en) 2016-06-20 2019-04-02 Incyte Corporation heterocyclic compounds as immunomodulators
MA45669A (en) 2016-07-14 2019-05-22 Incyte Corp HETEROCYCLIC COMPOUNDS USED AS IMMUNOMODULATORS
ES2941716T3 (en) 2016-08-29 2023-05-25 Incyte Corp Heterocyclic compounds as immunomodulators
SMT202100225T1 (en) 2016-12-20 2021-05-07 Astrazeneca Ab Amino-triazolopyridine compounds and their use in treating cancer
ES2899402T3 (en) 2016-12-22 2022-03-11 Incyte Corp Pyridine derivatives as immunomodulators
AU2017382870B2 (en) 2016-12-22 2022-03-24 Incyte Corporation Benzooxazole derivatives as immunomodulators
EP3558990B1 (en) 2016-12-22 2022-08-10 Incyte Corporation Tetrahydro imidazo[4,5-c]pyridine derivatives as pd-l1 internalization inducers
WO2018119286A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Bicyclic heteroaromatic compounds as immunomodulators
ES2874756T3 (en) 2016-12-22 2021-11-05 Incyte Corp Triazolo [1,5-A] pyridine derivatives as immunomodulators
EP3628043A4 (en) * 2017-05-15 2021-04-28 Recurium IP Holdings, LLC Analgesic compounds
JP2020524660A (en) 2017-06-14 2020-08-20 アストラゼネカ・アクチエボラーグＡｓｔｒａｚｅｎｅｃａ Ａｋｔｉｅｂｏｌａｇ 2,3-Dihydroisoindole-1-carboxamides useful as ROR-gamma modulators
CN107474043A (en) * 2017-09-13 2017-12-15 厦门稀土材料研究所 Nicotinic acid derivatives and their preparation methods and uses
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
WO2019071147A1 (en) 2017-10-05 2019-04-11 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce dux4 and downstream gene expression for the treatment of fshd
EP3728228A1 (en) 2017-12-22 2020-10-28 Ravenna Pharmaceuticals, Inc. Aminopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors
CR20200520A (en) 2018-03-30 2021-03-09 Incyte Corp Heterocyclic compounds as immunomodulators
WO2019217821A1 (en) 2018-05-11 2019-11-14 Incyte Corporation Tetrahydro-imidazo[4,5-c]pyridine derivatives as pd-l1 immunomodulators
EP3802517B1 (en) 2018-06-07 2022-12-21 Idorsia Pharmaceuticals Ltd Alkoxy-substituted pyridinyl derivatives as lpa1 receptor antagonists and their use in the treatment of fibrosis
CA3112549A1 (en) * 2018-09-13 2020-03-19 Eirion Therapeutics, Inc. Uses of plasminogen activator inhibitor 1 (pai-1) inhibitors
US11292782B2 (en) 2018-11-30 2022-04-05 Nuvation Bio Inc. Diarylhydantoin compounds and methods of use thereof
WO2020113094A1 (en) 2018-11-30 2020-06-04 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
CN111825605B (en) * 2019-04-19 2023-03-31 中国科学院上海药物研究所 Aryl ketone amide compound and preparation method and application thereof
TW202112767A (en) 2019-06-17 2021-04-01 美商佩特拉製藥公司 Aminopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors
AR119162A1 (en) 2019-06-18 2021-12-01 Idorsia Pharmaceuticals Ltd PYRIDIN-3-YL DERIVATIVES
EP4010342A1 (en) 2019-08-09 2022-06-15 Incyte Corporation Salts of a pd-1/pd-l1 inhibitor
WO2021067217A1 (en) 2019-09-30 2021-04-08 Incyte Corporation Pyrido[3,2-d]pyrimidine compounds as immunomodulators
CN114845709B (en) * 2019-11-05 2024-10-01 德米拉公司 MRGPRX2 antagonists for the treatment of inflammatory disorders
BR112022009031A2 (en) 2019-11-11 2022-10-11 Incyte Corp SALTS AND CRYSTALLINE FORMS OF A PD-1/PD-L1 INHIBITOR
KR20220109439A (en) 2019-12-04 2022-08-04 이도르시아 파마슈티컬스 리미티드 Combination of an azetidine LPA1 receptor antagonist with pirfenidone and/or nintedanib for use in the treatment of a fibrotic disease
CA3164134A1 (en) 2019-12-06 2021-06-10 Vertex Pharmaceuticals Incorporated Substituted tetrahydrofurans as modulators of sodium channels
US11866434B2 (en) 2020-11-06 2024-01-09 Incyte Corporation Process for making a PD-1/PD-L1 inhibitor and salts and crystalline forms thereof
US11780836B2 (en) 2020-11-06 2023-10-10 Incyte Corporation Process of preparing a PD-1/PD-L1 inhibitor
WO2022099075A1 (en) 2020-11-06 2022-05-12 Incyte Corporation Crystalline form of a pd-1/pd-l1 inhibitor
CN113209112B (en) * 2021-02-06 2021-12-24 广州市朝利良生物科技有限公司 Novel coronavirus resistant medicine based on ACE2 and S protein binding target and application thereof
SI4347031T1 (en) 2021-06-04 2026-01-30 Vertex Pharmaceuticals Incorporated N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamides as modulators of sodium channels
PE20250664A1 (en) 2022-02-14 2025-03-04 Accent Therapeutics Inc DHX9 RNA HELICASE INHIBITORS AND THEIR USES
WO2024059220A2 (en) * 2022-09-15 2024-03-21 Vanderbilt University 6,5 southwestern core compounds as mglu5 negative allosteric modulators and methods of making and using the same
CN118496159B (en) * 2024-07-18 2024-09-24 广州医科大学附属市八医院 Application of compound in preparation of medicine with liver fibrosis preventing and/or treating effect

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030008868A1 (en) * 2001-05-16 2003-01-09 Boehringer Ingelheim Pharmaceuticals, Inc. Compounds useful as anti-inflammatory agents
WO2005023761A2 (en) * 2003-09-11 2005-03-17 Kemia, Inc. Cytokine inhibitors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030008868A1 (en) * 2001-05-16 2003-01-09 Boehringer Ingelheim Pharmaceuticals, Inc. Compounds useful as anti-inflammatory agents
WO2005023761A2 (en) * 2003-09-11 2005-03-17 Kemia, Inc. Cytokine inhibitors
US20100273797A1 (en) * 2003-09-11 2010-10-28 Itherx Pharmaceuticals, Inc. Alpha-ketoamides and derivatives thereof

Also Published As

Publication number Publication date
AU2007257959A1 (en) 2007-12-21
TW200814998A (en) 2008-04-01
CL2007001670A1 (en) 2008-01-18
WO2007146712A3 (en) 2008-11-27
PE20080935A1 (en) 2008-08-02
AR061273A1 (en) 2008-08-13
EP2035005A2 (en) 2009-03-18
WO2007146712A2 (en) 2007-12-21
CA2691214A1 (en) 2007-12-21

Similar Documents

Publication Publication Date Title
EP2035005A4 (en) Therapy using cytokine inhibitors
EP2214669A4 (en) Cytokine inhibitors
EP2026843A4 (en) Therapeutic uses of inhibitors of rtp801l
GB2436010B (en) Therapy device
IL196559A0 (en) Combination therapy
GB0609492D0 (en) Therapeutic agents
SI2338487T1 (en) Combination therapy with PARP inhibitors
IL179398A0 (en) Dpp-ib inhibitors
GB0608928D0 (en) Therapeutic agents
IL193674A0 (en) Therapeutic piperazines as pde4 inhibitors
IL197818A0 (en) Multiple sclerosis therapy
GB0601962D0 (en) Therapeutic agents
IL196556A0 (en) Combination therapy
SI2094702T1 (en) Viral inhibitors
EP2054061A4 (en) Combination therapy
GB0616214D0 (en) Therapeutic Agents
IL198026A0 (en) Sequential combination therapy
ZA200902203B (en) Combination therapy
EP2131858A4 (en) P38 inhibitors
GB0611152D0 (en) Therapeutic agents
GB0421355D0 (en) Inhibitors
GB0620059D0 (en) Therapeutic agents
GB0620818D0 (en) Therapeutic agents
EP1816194A4 (en) Cancer-cell-specific proliferation inhibitors
GB0609676D0 (en) Therapeutic agents

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20090108

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK RS

RIN1 Information on inventor provided before grant (corrected)

Inventor name: SHUSTER, LEWIS, J.

Inventor name: PRYOR, KENT

Inventor name: MILLER, STEPHEN

Inventor name: LARSON, CHRISTOPHER, J.

Inventor name: KING, BERNARD

Inventor name: HEPBURN, BONNIE

Inventor name: GROVE, CARRIE, GAIL

Inventor name: ERNST, JUSTIN

Inventor name: DELAET, NANCY G., J.

Inventor name: CROWLEY, CONSTANCE, A.

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20110607

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20120105